Arrowstreet Capital Limited Partnership Buys 361,539 Shares of Hologic, Inc. (NASDAQ:HOLX)

Arrowstreet Capital Limited Partnership boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 27.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,687,347 shares of the medical equipment provider’s stock after buying an additional 361,539 shares during the period. Arrowstreet Capital Limited Partnership owned approximately 0.75% of Hologic worth $121,641,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in HOLX. General Partner Inc. acquired a new position in shares of Hologic during the fourth quarter worth approximately $26,000. Groupama Asset Managment lifted its holdings in shares of Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Down 1.6 %

Shares of HOLX stock opened at $61.32 on Monday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a market cap of $13.76 billion, a P/E ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The business has a 50-day moving average price of $65.24 and a two-hundred day moving average price of $73.24. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Evercore ISI reduced their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Raymond James restated an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.